Denali Therapeutics Inc. ( NASDAQ:DNLI – Free Report ) – Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for Denali Therapeutics in a report issued on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($4.51) for the year. The consensus estimate for Denali Therapeutics' current full-year earnings is ($3.53) per share. A number of other equities analysts have also weighed in on DNLI. Morgan Stanley lifted their price target on shares of Denali Therapeutics from $61.

https://www.dailypolitical.com/2023/07/15/cantor-fitzgerald-weighs-in-on-denali-therapeutics-inc-s-fy2024-earnings-nasdaqdnli.html

#dailypolitical